Терапия » НАРУШЕНИЯ ЛИПИДНОГО ОБМЕНА: ПРИНЦИПЫ ОБСЛЕДОВАНИЯ И МЕДИКАМЕНТОЗНАЯ ТЕРАПИЯ

НАРУШЕНИЯ ЛИПИДНОГО ОБМЕНА: ПРИНЦИПЫ ОБСЛЕДОВАНИЯ И МЕДИКАМЕНТОЗНАЯ ТЕРАПИЯ

DOI: https://dx.doi.org/10.18565/therapy.2023.9suppl.110-133

Полный текст статьи доступен
в "Библиотеке Врача"

Литература

1. Клинические рекомендации. Нарушения липидного обмена. Общероссийская общественная организация «Российское кардиологическое общество», автономная некоммерческая организация «Национальное общество по изучению атеросклероза», Российская ассоциация эндокринологов, Российское общество кардиосоматической реабилитации и вторичной профилактики (РосОКР), общероссийская общественная организация «Российское научное медицинское общество терапевтов», Евразийская ассоциация кардиологов, Евразийское общество терапевтов, общероссийская общественная организация «Российская ассоциация геронтологов и гериатров». Рубрикатор клинических рекомендаций Минздрава России. 2023. ID: 752. Доступ: https://cr.minzdrav.gov.ru/schema/752_1 (дата обращения – 01.10.2023).

2. Mach F., Baigent C., Catapano A.L. et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–88. https://dx.doi.org/10.1093/eurheartj/ehz455.

3. Ridker P.M., Rifai N., Cook N.R. et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005; 294(3): 326–33. https://dx.doi.org/10.1001/jama.294.3.326.

4. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021; 42(25): 2439–54. https://dx.doi.org/10.1093/eurheartj/ehab309.

5. Carey V.J., Bishop L., Laranjo N. et al. Contribution of high plasma triglycerides and low high density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low density lipoprotein cholesterol control. Am J Cardiol. 2010; 106(6): 757–63. https://dx.doi.org/10.1016/j.amjcard.2010.05.002.

6. Marston N.A., Giugliano R.P., Im K. et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: A systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019; 140(16): 1308–17. https://dx.doi.org/10.1161/CIRCULATIONAHA.119.041998.

7. Sacks F.M., Alaupovic P., Moye L.A. et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000; 102(16): 1886–92. https://dx.doi.org/10.1161/01.cir.102.16.1886.

8. National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002; 106(25): 3143–421.

9. Taylor F., Huffman M.D., Macedo A.F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; 2013(1): CD004816. https://dx.doi.org/10.1002/14651858.CD004816.pub5.

10. Cannon C.P., Blazing M.A., Giugliano R.P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372(25): 2387–97. https://dx.doi.org/10.1056/NEJMoa1410489.

11. Nordestgaard B.G., Chapman M.J., Humphries S.E. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34(45): 3478–90a. https://dx.doi.org/10.1093/eurheartj/eht273.

12. Yao Z. Human apolipoprotein C-III – a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins. Cardiovasc Hematol Disord Drug Targets. 2012; 12(2): 133–40. https://dx.doi.org/10.2174/1871529x11202020133.

13. Sacks F.M., Alaupovic P., Moye L.A. et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000; 102(16): 1886–92. https://dx.doi.org/10.1161/01.cir.102.16.1886.

14. Khan S.A., Naz A., Qamar Masood M., Shah R. Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Am J Cardiol. 2020; 134: 69–73. https://dx.doi.org/10.1016/j.amjcard.2020.08.018.

15. Fruchart J.C., Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006; 42(1): 39–64. https://dx.doi.org/10.1358/dot.2006.42.1.963528.

16. Keating G.M., Croom K.F. Fenofibrate. Drugs. 2007; 67(1): 121–53. https://dx.doi.org/10.2165/00003495-200767010-00013.

17. Bhatt D.L., Steg P.G., Miller M. et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019; 380(1): 11–22. https://dx.doi.org/10.1056/NEJMoa1812792.

18. Rohit D., Shankar J. Comparative study of atorvastatin and rosuvastatin in combination with fenofibrate in mixed hyperlipidemia. Int J Pharmacol and Clin Sci. 2016; 5(1): 25–31. https://dx.doi.org/10.5530/ijpcs.5.1.5.

19. Bangalore S., Kamalakkannan G., Parkar S., Messerli F.H. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med. 2007; 120(8): 713–19. https://dx.doi.org/10.1016/j.amjmed.2006.08.033.

20. Baumgartner A., Drame K., Geutjens S., Airaksinen M. Does the polypill improve patient adherence compared to its individual formulations? A systematic review. Pharmaceutics. 2020; 12(2): 190. https://dx.doi.org/10.3390/pharmaceutics12020190.

К содержанию номера